
The Biotech Startups Podcast
ExcedrAudio
- Format:
- Podcast
- New episodes:
- Several times a week
- Typical length:
- about 35 minutes
- Latest episode:
About this show
The Biotech Startups Podcast by Excedr features weekly conversations with founders, scientists, and investors driving biotech innovation. Host Jon Chee dives into the challenges of building biotech startups, from pre-seed to IPO. New episodes every Monday and Thursday.
Covers: biotech, startups, life sciences, entrepreneurship, clinical trials, drug development, venture capital, lab equipment
Show details and episodes come from the publisher's public feed at feeds.fame.so. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
This podcast covers the challenges of building biotech startups, through talks with founders, scientists and investors. Recent episodes cover disease signals before symptoms, a $500 lab that launched a company, and a company that reached almost $100 million without venture funding.
Cosmos
Similar in subject
- Business Of Biotech
Both cover: biotech, drug development, clinical trials - The a16z Show
Both cover: startups, venture capital - Y Combinator
Both cover: startups, venture capital, entrepreneurship
Similar shows
Explore more
Episodes
🧬 The Disease Signal Shows Up Before Symptoms | Ilya Burkov (1/4)
· 34 min
Need new or refurbished lab equipment? Excedr provides research labs with equipment leases on founder-friendly terms to support paths to exceptional outcomes. Learn more at https://www.excedr.com/ and explore our partner network: https://www.excedr.com/partners “Once you start measuring a joint or a tissue, you realize that the signal of disease is in the data long before anyone feels a symptom.” Ilya Burkov is Global Head of Scientific AI & Healthcare at Nebius. Ilya's parents had one rule for every childhood ambition, astronaut, fireman, chef: get a foundation first, then choose. He took it seriously. Sports year-round, science projects, Scouts trips, and around ten A levels, because biology, law, electronics, and further maths all seemed worth knowing. Where did the road really start? A hospital, he says, where he volunteered as a teenager, brought tea to long-term patients, and kept noticing that homes had Dysons while wards had old fans. That question about outdated hospital tech sent him hunting for a field that fused medicine with engineering, right as biomedical engineering degrees first appeared in the UK. He calls the course a Frankenstein of chemical, electronic, and mechanical engineering stitched onto anatomy and patient care. A master's in nanomedicine followed, just as stem cells and drug delivery were breaking through. His dissertation asked whether cartilage damage in osteoarthritis could be reversed, and that question pulled him toward the imaging biomarkers that flag disease long before symptoms. It ends with a stroke of luck: an interview he took out of curiosity while planning a move to France. Two hours later, the phone rang. Professor Ken Poole, the one interviewer he'd genuinely enjoyed, would be his PhD supervisor at Cambridge. Key Topics Covered: - Childhood split between sports and science projects - Parents' advice: build a foundation, then choose - Ten A levels across sciences and humanities - Growing up across Swindon, London, and Swansea - Teenage hospital volunteering and shadowing doctors - Spotting outdated technology on hospital wards - Biomedical engineering in its infancy - A Frankenstein degree combining engineering and medicine - Nanomedicine, drug delivery, and stem cells - Osteoarthritis dissertation on reversing cartilage damage - Imaging biomarkers that flag disease before symptoms - Bench skills: pipetting and cell culture - Choosing a PhD lab by chemistry, not plan - PhD research at Cambridge in clinical medicine If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep294 Find our guest, Ilya Burkov, at these links: LinkedIn: https://www.linkedin.com/in/ilyaburkov Website: https://nebius.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com/ Intro & Outro Songs Created by OkKyojin: https://flow.page/kyojin Resources & Articles: An introduction to high-content imaging: https://www.excedr.com/blog/an-introduction-to-high-content-imaging Confocal microscopy and imaging systems: https://www.excedr.com/blog/confocal-microscopy-and-imaging-systems What is live cell imaging: https://www.excedr.com/blog/what-is-live-cell-imaging MRI and medical imaging overview: https://www.excedr.com/blog/medical-imaging-and-radiology-overview How to modernize a clinical lab: https://www.excedr.com/blog/how-to-modernize-a-clinical-lab How to break into biotech BD as a…
Not rated yet🧬 The $500 Lab That Started a Company | James Evans Rerelease (3/3)
· 17 min
Need new or refurbished lab equipment? Excedr provides research labs with equipment leases on founder-friendly terms to support paths to exceptional outcomes. Learn more at https://www.excedr.com/ and explore our partner network: https://www.excedr.com/partners “I guess I'm scrappy.” You need a lab. James Evans found hoods for $500, looked at JLABS in San Diego, and walked away because the price and the fit were wrong. A decade later the company still hasn't taken the predetermined fundraising staircase. He went for a walk before the taping, told his wife those other podcast guests were rock stars, and landed on the only label that fit: scrappy. Every year brought a new punch: pandemic, credit, industry disruption. The lab learned to do more with less, then professional business development showed up and sales stopped being something you invent from being a customer. The work is still knocking on doors. Big pharma can take six months to send money. Government labs are that, on steroids. The forward look is off-the-shelf cell and gene therapy work, AAV uptake into human cell types, more revenue without pretending there's a secret sauce. Advice to his 21-year-old self is do more yoga. The people who still shock him are the ones who join the company and decide it can work. Key Topics Covered: - Finding a first lab and $500 hoods instead of JLABS - Choosing the bootstrap path on purpose - Why "scrappy" beats copying someone else's playbook - Doing more with less when every year brings a new crisis - Hiring professional business development as an inflection - Why big pharma paperwork can stall cash for six months - Cell and gene therapy services and AAV assays on the roadmap - Do more yoga, and thank the people who join anyway If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep293 Find our guest, James Evans, at these links: LinkedIn: https://www.linkedin.com/in/jamesgevans Website: https://phenovista.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com/ Intro & Outro Songs Created by OkKyojin: https://flow.page/kyojin Resources & Articles: Buying Used Lab Equipment vs. Leasing: https://www.excedr.com/blog/buying-used-equipment How Much Does a Fume Hood Cost?: https://www.excedr.com/blog/how-much-does-a-fume-hood-cost-pricing-breakdown A Guide to Writing a Small Business Grant Proposal: https://www.excedr.com/blog/how-to-write-a-small-business-grant-proposal Johnson & Johnson Innovation JLABS: https://jlabs.jnjinnovation.com/ Companies, Universities, & People Mentioned: Johnson & Johnson Innovation JLABS: https://jlabs.jnjinnovation.com/ Whitehead Institute: https://wi.mit.edu/ Timestamps: 00:00 Intro 01:05 You Need a Lab 01:12 JLABS Wasn't a Fit 03:25 Choose Your Own Adventure 03:38 I Guess I'm Scrappy 04:59 A New Challenge Every Year 05:47 Doing More With Less 06:39 Professional Business Development 08:16 Still Knocking on Doors 10:03 Big Pharma Takes Six Months 11:42 Government Labs on Steroids 12:18 AAV and Cell and Gene Therapy 14:39 The People Who Join Your Company 15:13 Do More Yoga 16:41 Outro The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there.…
Not rated yet🧬 Science Is Twenty Percent of the Problem | James Evans Rerelease (2/3)
· 21 min
Need new or refurbished lab equipment? Excedr provides research labs with equipment leases on founder-friendly terms to support paths to exceptional outcomes. Learn more at https://www.excedr.com/ and explore our partner network: https://www.excedr.com/partners “The science does need to be good, but it's probably 10 or 20% of the problem.” Paul Matsudaira took a job in Singapore, and James Evans did not wake up one morning craving entrepreneurship. He left MIT's Whitehead Institute, bounced through venture-backed biotechs, and got a baptism of fire defending data in rooms that wanted a fight. One San Diego client won a contract, and that was enough to plant PhenoVista in California with a year of runway and no paying customers yet. The culture shock was the point. Academia does not restructure a lab because a fund's priorities changed. Private-sector science does, and it felt unfair. His wife is the reason the company exists. She believed first, then kept bringing home the HR and ops problems nobody warns you about. If people had told him, he says he wouldn't have listened. iPS-derived cells were still new, the market had a hole, and they never wrote a business plan. They mapped rent, salaries, and grants on the back of the old-fashioned way, because James had no fundraising network from those earlier VC-backed seats. Bootstrap was necessity, not branding. Getting Erica on payroll was the moment the tissue-culture-in-a-hot-room era had to get slightly more professional. Key Topics Covered: - Leaving MIT when Paul Matsudaira moved to Singapore - The baptism of fire inside venture-backed biotech - Moving the company to San Diego on a client contract - A year of runway and zero paying clients - Why academic culture and VC-backed science collide - Starting PhenoVista because his wife believed first - Science as 10 to 20 percent of the actual problem - iPS cells, no business plan, and bootstrap by necessity If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. ────────────────────────────────────────────────── Links: Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep292 Find our guest, James Evans, at these links: LinkedIn: https://www.linkedin.com/in/jamesgevans Website: https://phenovista.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com/ Intro & Outro Songs Created by OkKyojin: https://flow.page/kyojin Resources & Articles: How to Choose the Right Contract Research Organization: https://www.excedr.com/blog/contract-research-organizations A Guide to Writing a Small Business Grant Proposal: https://www.excedr.com/blog/how-to-write-a-small-business-grant-proposal How Do Core Labs Support Life Science Research?: https://www.excedr.com/blog/core-labs Companies, Universities, & People Mentioned: Whitehead Institute: https://wi.mit.edu/ Massachusetts Institute of Technology: https://www.mit.edu/ National University of Singapore: https://www.nus.edu.sg/ Timestamps: 00:00 Intro 01:19 Paul Moves to Singapore 04:06 Baptism of Fire 04:16 A Client in San Diego 05:27 No Paying Clients and a Year of Runway 07:26 Getting Erica 09:06 Academia Meets Venture Backing 09:31 Restructuring That Felt Unfair 12:42 I Wouldn't Have Started Without My Wife 14:05 You Wouldn't Listen If They Told You 14:15 Science Is Twenty Percent of the Problem 15:45 iPS Cells and a Gap in the Market 17:17 We Never Wrote a Business Plan 18:32 Bootstrap by Necessity…
Not rated yet🧬 Kickflips and Bacterial Pellets Built a Founder | James Evans Rerelease (1/3)
· 27 min
Need new or refurbished lab equipment? Excedr provides research labs with equipment leases on founder-friendly terms to support paths to exceptional outcomes. Learn more at https://www.excedr.com/ and explore our partner network: https://www.excedr.com/partners “Yeah, tastes like corn, doesn't it?” James Evans calls himself a late starter. Childhood in the UK was skateboarding and video games, not science kits. His dad was an engineer, and his mom was a nurse, which only looks like a straight line if you draw it afterwards. Science wasn't in the house. Soccer was mainstream. Skateboarding was not, and that counterculture stubbornness is the part he still recognizes in company building. The fuse lit in Belgium. Coventry University's Erasmus year put him in a Liege lab resuspending bacterial pellets with a mouth pipette, the kind of training that includes a French-speaking grad student shrugging off a mouthful of culture with "tastes like corn." He came home, actually applied himself, and later landed in an endocrinology lab as the imaging outlier. One accidental meeting stretched into a decade at MIT's Whitehead Institute. At the Whitehead-MIT Bioimaging Center, he learned the habit he still sells: don't do time-resolved FRET in 3D because it sounds fancy. Ask what data you need and take the fastest reliable path. Paul Matsudaira had gone to grad school with Lance Taylor, who originated high-content screening, and that mix of academic freedom and automated platforms is the through-line into PhenoVista. Key Topics Covered: - Why skateboarding and video games are underrated founder training - A UK childhood with no science in the house - The Erasmus year in Belgium that finally switched the light on - Mouth pipetting, bacterial pellets, and "tastes like corn" - Coventry versus the Cambridge-Oxford hierarchy - Ten years at MIT's Whitehead Institute Bioimaging Center - High-content screening versus Swiss-watchmaker imaging - The fastest path to the data, not the fanciest assay If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep291 Find our guest, James Evans, at these links: LinkedIn: https://www.linkedin.com/in/jamesgevans Website: https://phenovista.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com/ Intro & Outro Songs Created by OkKyojin: https://flow.page/kyojin Resources & Articles: High-Content Imaging Guide: https://www.excedr.com/blog/an-introduction-to-high-content-imaging How Do Core Labs Support Life Science Research?: https://www.excedr.com/blog/core-labs Choosing the Right Microscope for Your Workflow: https://www.excedr.com/blog/choosing-the-right-microscope-for-your-workflow Confocal Microscopy and Imaging Systems: https://www.excedr.com/blog/confocal-microscopy-and-imaging-systems Companies, Universities, & People Mentioned: Whitehead Institute: https://wi.mit.edu/ Massachusetts Institute of Technology: https://www.mit.edu/ Harvard University: https://www.harvard.edu/ Coventry University: https://www.coventry.ac.uk/ University of Liège: https://www.uliege.be/cms/c_8699436/en/uliege Timestamps: 00:00 Intro 01:40 A Late Starter 03:16 Science Kits, Not Science Class 04:14 Kickflips and Perseverance 05:00 Counterculture on a UK Skateboard 05:34 Mrs. Akhtar and Tractable Biology 07:05 The Erasmus Year in Belgium 08:31 Tastes Like Corn 09:17 Coventry Versus Cambridge…
Not rated yet🧬 Almost $100 Million. No Venture. | Steve Visco Rerelease (3/3)
· 36 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “We've never actually taken venture capital.” Steve Visco grew PolyPlus Battery Company on government contracts instead of a stack of tiny SBIRs. Lawrence Berkeley had already taught him how to write large proposals. The danger, he says, is chasing money that pulls the company off its North Star. Once you sign, you cannot renegotiate the work. You get reports, audits, and no BMWs in the parking lot. ARPA-E will kill a grant that stalls. His grant-writing rule is the same as a venture pitch: why should anyone care, who is on the team, and don't ask for too little. They started on angels, then a chemical company paid the R&D bills. Strategic investors followed. They have never taken venture. First CEO Rudolph Hurwich did not want it. Venture fails fast. Grants and angels do not take the company. Manufacturing money later showed up in specialized government programs, including a seawater-battery line. Steve's play for corporates is not a cold email. Give a talk that scouts cannot ignore, or earn a press hit, and let them come to you. Japanese partners move by consensus and assume Americans exaggerate. Some Korean partners decide fast and stay on you. Recruiting in California is a fight. Manufacturing is going to Indiana: dry rooms, ISO, a general manager, and a pro-business state. Asked what he would tell his 21-year-old self, Steve lands on follow the work that still excites you. He thanks Donna, then Rudy, who was on Nixon's enemies list, made the cover of Time with Dymo, and taught a 1960s skeptic that builders can be decent people. Key Topics Covered: - Non-dilutive grants instead of living on SBIRs - Close to $100 million in government money - Write the proposal so the North Star is already in the statement of work - Audits, reporting, and ARPA-E's high bar - Don't ask for too little - Acting classes, storytelling, and a delayed Nobel - Angels and strategics, never venture - Why Rudy Hurwich kept VCs out - Seawater batteries and manufacturing grants - Conference talks that make corporates walk up after - Japanese diligence versus Korean speed - Hiring in California, building in Indiana - Advice to a 21-year-old, and a shout-out to Rudy If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep290 Find our guest, Steve Visco, at these links: LinkedIn: https://www.linkedin.com/in/steven-j-visco-2910b57 Website: https://polyplus.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com/ Intro & Outro Songs Created by OkKyojin: https://flow.page/kyojin Resources & Articles: Non-dilutive capital: https://www.excedr.com/blog/the-benefits-of-non-dilutive-capital Grant funding: https://www.excedr.com/resources/grants-public-funding-biotech-startups Grant proposals: https://www.excedr.com/blog/how-to-write-a-grant-proposal-for-research SBIR grants: https://www.excedr.com/blog/sbir-grants-guide Survive without VC: https://www.excedr.com/resources/can-biotech-startups-survive-without-vc-funding…
Not rated yet🧬 “We're Going to Burn Your Company to the Ground” | Steve Visco Rerelease (2/3)
· 34 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “We're going to burn your company to the ground.” Steve Visco's spinout found its first CEO in the audience. Rudolph Hurwich had already built Dymo, cashed out, and was hunting for another shot at something big. He offered to raise the angel round and take the job when Steve said he wasn't ready. The founding four were faculty: Steve, Lutgard De Jonghe at Berkeley, Michel Armand in Montreal and Grenoble, and Meilin Liu at Georgia Tech. They opened the doors in 1991. Sony introduced lithium-ion the same year. The bar moved overnight. US names like Duracell never caught up. Korea did. Then China. Battery production started to look like the new oil. For about a decade the company lived on fundamental patents and joint development with chemical firms such as DuPont, not on shipping cells. Two years in, a Silicon Valley lead-acid supplier wanted to merge and IPO on the back of three Berkeley Lab patents. Diligence found the lab had skipped the maintenance fees. The patents were abandoned, then reinstated after a fight with the patent office. A competitor's packs exploded at Motorola two days before the offering. The bankers said no more battery IPOs. Later, a lithium-sulfur follower copied claims, sued, and sent a CEO to Berkeley with a threat to burn the company down. They hired the lawyer who wrote the book on interference law and won. Steve's advice from the scar tissue: license by geography or application, never the whole stack, and build a picket fence, not one patent. Key Topics Covered: - Finding a CEO at a Berkeley-Stanford pitch - Four faculty founders across three countries - Sony ships lithium-ion in 1991 - Japan, Korea, China, and the new oil - A decade as a licensing company - Lead-acid for Apple and a red herring - Berkeley Lab missed the maintenance fees - Exploding packs and a killed IPO - Lithium-sulfur patent trolls - An interference suit backed by a hedge fund - Winning at the USPTO appellate court - License by geography, not the whole company - Picket fences, PCT filings, and in-house IP If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep289 Find our guest, Steve Visco, at these links: LinkedIn: https://www.linkedin.com/in/steven-j-visco-2910b57 Website: https://polyplus.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com/ Intro & Outro Songs Created by OkKyojin: https://flow.page/kyojin Resources & Articles: IP strategy for biotechs: https://www.excedr.com/resources/intellectual-property-strategy-for-biotechs How to protect your IP: https://www.excedr.com/resources/how-to-protect-your-intellectual-property How investors evaluate life sciences IP: https://www.excedr.com/resources/how-investors-evaluate-life-sciences-ip How patent licensing works: https://www.excedr.com/resources/how-patent-licensing-works PCT (WIPO): https://www.wipo.int/pct/en/ Federal Circuit: https://www.cafc.uscourts.gov/ Companies, Universities, & People Mentioned: DuPont:…
Not rated yet🧬 He Chose Santa Barbara Over Icebergs | Steve Visco Rerelease (1/3)
· 35 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “He says, no, I'm serious. Icebergs. I'm going to Santa Barbara.” Steve Visco was an introverted kid with a microscope, pond water, and books on Louis Pasteur and Jonas Salk. School science lagged years behind what he was already doing at home. Literature almost pulled him into writing instead of the lab. He still treats writing as a leadership skill, because too many scientists cannot explain why their work matters. A high-school rock band got him used to being watched. That comfort later showed up in grant pitches. His father started as an auto mechanic, then taught at a vocational high school while earning degrees on nights and weekends. The deal at home was two comic books for every classic novel. At UMass, Steve stayed pre-med until a professor pulled him into real chemistry on a valley about to be flooded for a reservoir. He published as an undergrad, then walked away from medicine. Brown taught him electrochemistry on metal carbonyls, not batteries. A postdoc in Newfoundland came with a ferry and a warning about icebergs. He took Santa Barbara instead. John Kennedy's lab was already poking at solid-state batteries in the early 1980s. Work from 1982 still sits under what PolyPlus Battery Company does now. Lawrence Berkeley National Lab felt like Bell Labs when Steve arrived, until the political question hit: why do taxpayers need these labs? Training scientists was not enough. Labs stood up tech transfer offices. Steve's group became the second company launched out of Berkeley Lab after a Wall Street Journal reporter, who wanted three lines, gave him a quarter page instead. Key Topics Covered: - Childhood science, vaccines, and a home microscope - Literature versus the lab, and why scientists need to write - Lead guitar and learning an audience - A father who earned degrees on weekends - UMass research on a flooded valley - Walking away from pre-med - Brown, metal carbonyls, and electrochemistry - Newfoundland icebergs versus Santa Barbara - John Kennedy and solid-state batteries before the boom - Why national labs built tech transfer offices - The second company out of Berkeley Lab - A Wall Street Journal call that started a company If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep288 Find our guest, Steve Visco, at these links: LinkedIn: https://www.linkedin.com/in/steven-j-visco-2910b57 Website: https://polyplus.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com/ Intro & Outro Songs Created by OkKyojin: https://flow.page/kyojin Resources & Articles: Tech transfer and spinning out What is technology transfer: https://www.excedr.com/blog/what-is-tech-transfer How to spin out of academia into a startup: https://www.excedr.com/resources/how-to-spin-out-of-academia-and-into-a-startup Patent licensing How patent licensing works: https://www.excedr.com/resources/how-patent-licensing-works Angel funding How to raise money from angel investors:…
Not rated yetIf It's Getting More Complex, You're Going the Wrong Way | Scott Chetham (4/4)
· 40 min
Excedr provides research labs with equipment leases on founder-friendly terms to support paths to exceptional outcomes. Learn more at https://www.excedr.com/partners. “If things are getting more complex, you're going in the wrong direction.” Scott Chetham explains why he left Google and Verily to tackle the unglamorous planning work that slows clinical development. He recounts sketching the company in Costa Rica, raising a pre-napkin-stage round with Polaris, finding an early customer, and adapting when COVID-19 disrupted pharma economics. He also traces Faro's evolution from a scenario-planning calculator into a broader platform for protocol review, data transformation, automation, and research support. The conversation covers regulated AI, the limits of historical data and trial simulation, customer trust, founder stamina, enterprise transformation, and the shift from pushing a market to being pulled by it. Scott closes with the advice that has stayed with him: fight complexity everywhere. Key Topics Covered: - Leaving Google and Verily to solve clinical development's planning bottleneck - Building a company from a Costa Rica planning retreat - Raising a pre-napkin-stage venture round with Polaris - Finding early customers during COVID-19 disruption - The realities of second-time founding and balancing family life - Referral-driven enterprise sales in a trust-sensitive industry - Faro's evolution from a clinical trial cost calculator to an automation platform - Knowledge graphs, data transformation, and constrained LLM workflows - Automating protocol review and electronic data capture programming - Why pre-2019 clinical data may mislead modern trial design - The limits of replacing clinical trials with simulations - Transforming large pharma organizations under pressure - Moving from pushing automation to responding to customer demand - Founder leverage, sustainable pace, and organizational scale - Why increasing complexity is a warning sign If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 TBSP YouTube: https://www.youtube.com/@thebiotechstartupspodcast TBSP website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep287 Find our guest, Scott Chetham, at these links: LinkedIn: https://www.linkedin.com/in/scott-chetham-2949001 Website: https://farohealth.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin: https://flow.page/kyojin Resources & Articles: Faro Health: https://farohealth.com/ Polaris: https://www.polaris.vc/ Verily: https://verily.com/ Anthropic: https://www.anthropic.com/ ClinicalTrials.gov: https://clinicaltrials.gov/ Companies, Universities, & People Mentioned: Google: https://www.google.com/ Verily: https://verily.com/ Polaris: https://www.polaris.vc/ Anthropic: https://www.anthropic.com/ Merck: https://www.merck.com/ Meta: https://about.meta.com/ Timestamps: 00:00 Intro 01:44 Leaving Google and Verily 02:50 A Company Sketched in Costa Rica 03:28 COVID Disrupts the Early Market 04:39 The Older Founder Advantage 05:44 Trust, Referrals, and Scaling 10:21 From Fancy Calculator to Platform 12:52 Regulated AI Needs Guardrails 14:45 Why the Ecosystem Must Work Together 17:29 When More Data Makes Things Worse 18:44 The Limits of Trial Simulation 24:40 Transforming Pharma Before Costs Break It 27:30 From Pushing to Being Pulled 37:20 Fight Complexity Everywhere 39:16 Outro The Biotech…
Not rated yetThe Clinical Trial Bottleneck Is Not Discovery | Scott Chetham (3/4)
· 30 min
Excedr provides research labs with equipment leases on founder-friendly terms to support paths to exceptional outcomes. Learn more at https://www.excedr.com/partners. “Our problem is the clinical funnel to shove things through this 12 year development cycle and the amount of capital it takes.” Clinical development is not a simple scale game. Scott explains why large pharmaceutical companies can behave like highly optimized development machines, while smaller biotechs absorb the full cost of delays, amendments, interim analyses, and underused teams. The conversation then moves to the decisions that determine whether a trial succeeds: what to measure, whom to enroll, and when to measure it. Scott uses Amgen's osteoporosis strategy to show how a focused endpoint and staged market entry can outperform an attempt to capture everything at once. Scott also breaks down adaptive trials, global trial planning, patient consent, and the role of AI in compressing months of research into rapid scenario analysis. Automation can map the landscape, but judgment remains essential when the biology is new and the stakes are high. Key Topics Covered: - Nonlinear clinical development economics - Why large pharmaceutical companies gain efficiency from fixed development infrastructure - The cost burden of amendments, interim analyses, and idle clinical teams - The division of labor between biotech discovery and pharmaceutical development - mRNA manufacturing and Moderna's personalized vaccine production model - Clinical endpoints as a strategic and competitive differentiator - Amgen's staged osteoporosis strategy - Adaptive trials and preplanned endpoint changes - Clinical trial failure rates and increasing biological complexity - Why clinical development, rather than molecule discovery, constrains the drug pipeline - The human realities of patient consent and family trust - Using AI and machine learning for protocol research and scenario modeling - Global trial sequencing, country selection, cost, and enrollment optimization If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 TBSP YouTube: https://www.youtube.com/@thebiotechstartupspodcast TBSP website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep286 Find our guest, Scott Chetham, at these links: LinkedIn: https://www.linkedin.com/in/scott-chetham-2949001 Website: https://farohealth.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin: https://flow.page/kyojin Resources & Articles: ClinicalTrials.gov: https://clinicaltrials.gov/ Amgen: https://www.amgen.com/ Merck: https://www.merck.com/ Companies, Universities, & People Mentioned: Merck: https://www.merck.com/ Amgen: https://www.amgen.com/ Google: https://www.google.com/ Verily: https://verily.com/ Timestamps: 00:00 Intro 01:47 Why Clinical Economics Are Nonlinear 01:51 The Pharmaceutical Development Machine 04:29 What Makes Moderna Scalable 07:13 The Endpoint Is the Differentiator 08:07 How Amgen Beat the Broader Strategy 09:10 Where Human Judgment Still Wins 10:41 Why Clinical Trials Fail 11:53 The Bottleneck Is the Clinical Funnel 12:35 The Parts of Trials AI Cannot Automate 14:43 Adaptive Trials and Planned Pivots 16:19 Automating the Research Behind Trial Design 21:56 Why Domain Expertise Still Matters 26:03 Optimizing Global Trial Scenarios 29:09 Outro The Biotech Startups Podcast gives you a front-row seat to the…
Not rated yetKnowledge Is Now a Commodity | Scott Chetham (2/4)
· 34 min
Excedr provides research labs with equipment leases on founder-friendly terms to support paths to exceptional outcomes. Learn more at https://www.excedr.com/partners. “Knowledge is now a commodity, and it's your ability to ask the right question and the right next question that is really where the value is.” Scott Chetham explains why he left academia, how applied physics and industry-sponsored research prepared him for commercial healthcare, and what he learned leading technology and commercialization at ImpediMed. He discusses lymphedema detection, body composition monitoring, early GLP-1 research, and the long path from clinical measurement to drug development. The conversation then turns to scaling teams through uncertainty. Scott shares how company growth creates organizational whiplash, why founders often underestimate the need for change management, and how leaders can stay close to what employees and customers are actually experiencing. Scott also describes the shift from software and AI as coding problems to problems of product judgment, prioritization, alignment, and quality assurance. He outlines how better automation could cut roughly half the internal work involved in clinical development, while explaining why rigorous verification and human decision-making remain essential. Key Topics Covered: - Leaving academia for direct impact in healthcare - Applied physics, biomedical engineering, and industry-sponsored research - How asking the right scientific question shapes clinical development - ImpedMed's lymphedema detection technology - Body composition monitoring in obesity and drug research - Early GLP-1 clinical research and pharmaceutical partnerships - The progression from diagnostic devices to clinical development software - Change management inside fast-growing healthcare companies - Founder comfort with uncertainty, pivots, and execution - Keeping leadership connected to employees as teams scale - AI-driven shifts in product development and engineering bottlenecks - Front-loading quality assurance for regulated workflows - Reducing clinical development time, labor, and cost If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 TBSP YouTube: https://www.youtube.com/@thebiotechstartupspodcast TBSP website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep285 Find our guest, Scott Chetham, at these links: LinkedIn: https://www.linkedin.com/in/scott-chetham-2949001 Website: https://farohealth.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin: https://flow.page/kyojin Resources & Articles: ImpediMed: https://impedimed.com/ Novo Nordisk: https://www.novonordisk.com/ ClinicalTrials.gov: https://clinicaltrials.gov/ Google X: https://x.company/ Verily: https://verily.com/ Companies, Universities, & People Mentioned: ImpediMed: https://impedimed.com/ Novo Nordisk: https://www.novonordisk.com/ Novartis: https://www.novartis.com/ Versant Ventures: https://www.versantventures.com/ Google: https://www.google.com/ Google X: https://x.company/ Verily: https://verily.com/ DeepMind: https://deepmind.google/ Meta: https://about.meta.com/ Timestamps: 00:00 Intro 01:36 Why Scott Left Academia 03:42 Applied Physics in Clinical Research 04:52 The Value of Asking Better Questions 04:56 From Research to Industry 07:17 Scaling Through Change Management 09:30 The Whiplash of Company Growth 13:20 Staying Close to…
Not rated yetThe Hard Part Starts After the Demo | Scott Chetham (1/4)
· 35 min
Excedr provides research labs with equipment leases on founder-friendly terms to support paths to exceptional outcomes. Learn more at https://www.excedr.com/partners. “Two-thirds of our work is QA. It's not the development anymore. It's how do you ensure it's doing what you think it's doing and that it will keep doing it, it won't drift.” Scott Chetham traces the influences that shaped his path into life sciences, from growing up on Australia's Gold Coast and watching his parents build careers through work and education to studying the intersection of engineering and medicine. He shares how a combined degree, early exposure to hospitals, and an unusual appetite for difficult problems pushed him toward biomedical research. The conversation then moves into the rapid evolution of cardiac electrophysiology, including early catheter mapping, implantable devices, and clinical trial work at St. Andrews War Memorial Hospital. Scott and Jon also examine a problem that has become central to deploying AI in regulated fields: polished outputs can still be wrong, models can drift, and rigorous QA, source grounding, and human judgment are not optional. Key Topics Covered: - Growing up on Australia's Gold Coast - Lessons from early work at SeaWorld - The influence of Scott's parents and their path into higher education - Biology, functional anatomy, computers, and the decision to pursue healthcare - The value and limits of a highly regimented boarding-school education - AI-generated misinformation in venture research and company diligence - Why human interviews still matter in an AI-saturated research process - Guardrails, source-of-truth data, and degradation across repeated AI generations - Scott's combined engineering and medical training - Early neural-network research for cardiac signal interpretation - Cardiac electrophysiology, pacemakers, ICDs, and catheter ablation - The transition from open-chest procedures to closed-chest 3D cardiac mapping - Why AI deployment requires extensive QA, model monitoring, and human judgment If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 TBSP YouTube: https://www.youtube.com/@thebiotechstartupspodcast TBSP website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep284 Find our guest, Scott Chetham, at these links: LinkedIn: https://www.linkedin.com/in/scott-chetham-2949001 Website: https://farohealth.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin: https://flow.page/kyojin Resources & Articles: Stanford Medicine: https://med.stanford.edu/ Google Model Cards: https://modelcards.withgoogle.com/about Medtronic: https://www.medtronic.com/ Companies, Universities, & People Mentioned: SeaWorld: https://seaworld.com/ KPMG: https://kpmg.com/ Google: https://www.google.com/ Stanford University: https://www.stanford.edu/ Medtronic: https://www.medtronic.com/ Anthropic: https://www.anthropic.com/ Timestamps: 00:00 Intro 02:38 Growing Up on the Gold Coast 03:05 The SeaWorld Production Line 04:02 A Family Built Around Education 07:18 Biology, Computers, and Healthcare 08:24 Learning to Lead Outside the Classroom 10:51 When AI Gets the Story Wrong 14:49 Guardrails Against Model Drift 16:27 Bridging Engineering and Medicine 18:24 Neural Networks Before the Boom 19:11 Inside the Cardiac Cath Lab 19:48 From Clinical Work to Research 24:58 The Revolution in Cardiac Mapping 29:43 Why QA Is the…
Not rated yetLetting Go Is a Leadership Skill | Leslie Loveless (4/4)
· 37 min
Excedr helps life science companies get the lab equipment they need through flexible leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “If you can overthink all the bad stuff, why can't you overthink all the good stuff?” As Slone Partners grew beyond its original five-person team, Leslie Loveless had to confront one of the hardest parts of leadership: letting go. She talks about delegation, resisting the urge to rewrite everyone else's work, and learning that a different approach can still be the right approach. Leslie also explains how Slone protects culture by listening for what different people need. The firm's culture ambassador helps turn that feedback into action, while Leslie reflects on when leaders should solve a problem, when they should simply listen, and why some issues need time to breathe. Looking ahead, Leslie sees growing demand across medtech, healthtech, AI, and machine learning. She discusses the limits of recruiting from the same blue-chip companies, the realities of relocation and family decisions, the tension between remote and on-site work, and the people who helped her build the firm. Key Topics Covered: - Delegation and the difficulty of letting go as a company grows - Accepting different communication and work styles - Listening before jumping into problem-solving mode - Using a culture ambassador to gather and act on employee feedback - Building executive team leadership inside a growing search firm - AI and machine learning hiring demand in medtech and healthtech - Why technology can improve executive search without replacing human intuition - Expanding candidate searches beyond blue-chip companies and primary biotech markets - Relocation, family considerations, and executive hiring decisions - Balancing remote, hybrid, and on-site work models - The value of documenting institutional knowledge in distributed organizations - Gratitude toward family, employees, and long-term clients If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep283 Find our guest, Leslie Loveless, at these links: LinkedIn: https://www.linkedin.com/in/leslieloveless1 Slone Partners: https://slonepartners.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin OkKyojin: https://flow.page/kyojin Resources & Articles: Slone Partners: https://slonepartners.com/ Faro Health: https://farohealth.com/ NVIDIA: https://www.nvidia.com/ Purdue University: https://www.purdue.edu/ Companies, Universities, & People Mentioned: Purdue University: https://www.purdue.edu/ Faro Health: https://farohealth.com/ Timestamps: 00:00 Intro 01:53 The Hard Part of Growing Beyond Five People 02:43 Learning When to Speak Up 03:25 Different Ways of Doing the Work 04:09 A Type A Leader Learns to Slow Down 04:36 People Need Different Things 05:07 The Culture Ambassador Role 07:39 When Listening Beats Problem Solving 09:43 Giving Problems Time to Breathe 12:32 Slone's Next Growth Areas 12:55 Creating an Executive Team Mindset 13:58 Technology, Efficiency, and Human Intuition 17:33 The NBA Draft Mentality in AI Recruiting 19:16…
Not rated yetThe Employee Number Five Leap That Built a Relationship Business | Leslie Loveless (3/4)
· 33 min
Excedr helps life science companies get the lab equipment they need through flexible leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “People are our clients. People are our product, and connecting them is what we do.” Leslie Loveless joined Slone Partners after a major personal transition, leaving a large healthcare company to become employee number five at a small recruiting firm. She hadn't worked in recruiting before, and at the time, she didn't fully appreciate how big the leap would be. Leslie revisits the firm's early startup days, when meetings ran through improvised conference calls and the team relied on paper, notebooks, and spreadsheets. She also explains how Slone expanded beyond laboratory and diagnostics recruiting into biotech, research tools, pharma services, healthtech, digital health, and academic medicine. At the center of that growth is a relationship-driven approach to search. Leslie discusses investor and portfolio-company relationships, the importance of long-tenured teams, the difference between an experienced candidate and the right fit, and why attitude matters when the work is inherently unpredictable. Key Topics Covered: - Leaving a large healthcare company to join a five-person recruiting firm - Adopting Leslie's daughter during her first year at Slone Partners - Evaluating whether candidates can thrive in startup environments - Slone Partners' expansion beyond laboratory and diagnostics recruiting - Executive search relationships with venture capital and private equity investors - Hiring across biotech, genomics, research tools, pharma services, and healthtech - The changing role of diagnostics, liquid biopsy, prognostics, and early detection - Why long team tenure can compound relationships and industry knowledge - Reading candidate motivations, behavior, and company fit beyond the resume - Why attitude and resilience matter in a people-centered business If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep282 Find our guest, Leslie Loveless, at these links: LinkedIn: https://www.linkedin.com/in/leslieloveless1 Slone Partners: https://slonepartners.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin OkKyojin: https://flow.page/kyojin Resources & Articles: Slone Partners: https://slonepartners.com/ Labcorp: https://www.labcorp.com/ Quest Diagnostics: https://www.questdiagnostics.com/ NVIDIA: https://www.nvidia.com/ Companies, Universities, & People Mentioned: LabCorp: https://www.labcorp.com/ NVIDIA: https://www.nvidia.com/ Jensen Huang: https://en.wikipedia.org/wiki/Jensen_Huang Purdue University: https://www.purdue.edu/ Timestamps: 00:00 Intro 01:39 The Promotion That Coincided With Adoption 02:16 A Phone Call, Then a New Baby 02:36 Reconnecting With Adam 03:01 Becoming Employee Number Five 03:33 A Leap She Didn't Fully Understand 07:17 Hardcore Startup Mode 07:44 Who Can Really Thrive at a Startup? 08:49 Why Leslie Still Uses Notebooks 11:31 When the Original Market Changes 11:54 Building Around Investor Relationships 12:32 The Expanding Life Sciences…
Not rated yetWinning President's Club with Zero Sales Experience | Leslie Loveless (2/4)
· 27 min
Excedr helps life science companies get the lab equipment they need through flexible leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “No one looks at a teacher's resume and thinks they can go sell.” Leslie Loveless leaves the classroom for pharmaceutical sales in 1999, a coveted industry at the time. She describes the culture shock of moving from a school building into a territory-based role, where her days meant driving between providers, managing her own schedule, and learning to sell one-to-one. The transition wasn't easy on paper. Recruiters and hiring managers saw that Leslie lacked sales experience, but they missed the skills she had built teaching: public speaking, preparation, performance, and the ability to hold an audience's attention. At Takeda, those skills helped her win President's Club in both of her first two years. Leslie then explains how a call from Adam Slone led her to Quest Diagnostics, where she moved quickly from individual sales into national sales training. The selling motion was completely different: hospital and laboratory deals required service, economic value, and buy-in from medical, operational, procurement, and financial stakeholders. Key Topics Covered: - Translating classroom teaching skills into pharmaceutical sales - Pharmaceutical sales training and role-playing - Takeda and the importance of partner reps - Winning President's Club without prior sales experience - Why scientific founders need commercial awareness - Working backward from market adoption and investor sentiment - Moving from provider sales to hospital and health system sales - Enterprise sales in laboratory medicine - Stakeholder alignment across procurement, finance, lab services, and clinical leadership - Service quality, turnaround time, and specimen reliability - Economic value propositions in healthcare sales If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep281 Find our guest, Leslie Loveless, at these links: LinkedIn: https://www.linkedin.com/in/leslieloveless1 Slone Partners: https://slonepartners.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin OkKyojin: https://flow.page/kyojin Resources & Articles: Takeda: https://www.takeda.com/ Quest Diagnostics: https://www.questdiagnostics.com/ Companies, Universities, & People Mentioned: Takeda: https://www.takeda.com/ Quest Diagnostics: https://www.questdiagnostics.com/ Timestamps: 00:00 Intro 01:37 Choosing Pharmaceutical Sales 02:38 The Teacher Resume Problem 02:54 Two Weeks Of Training In Chicago 04:04 Learning The Territory 04:27 Freedom Outside The Classroom 05:07 Public Speaking As A Sales Skill 05:53 Selling One To One 08:47 Two Presidents Club Wins 08:54 The Value Of Orthogonal Experience 10:16 Connecting Science To The Market 13:12 Adam Slone's First Call 14:50 Joining Quest Diagnostics 15:25 An Unexpected Training Role 18:05 Selling Into Health Systems 20:39 Service And Economics Win Enterprise Deals 26:22 Outro The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech.…
Not rated yetHow Teaching High School Prepares You to Run a Company | Leslie Loveless (1/4)
· 34 min
Excedr helps life science companies get the lab equipment they need through flexible leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “You need to really be in tune with what's being heard and received and understood.” Leslie Loveless starts at the beginning: growing up in a close-knit Indiana family, watching her father build a career as a pharmacist, and learning early that education mattered even if the eventual career path was left up to her. She explains how high school shifted her interests from mathematics to English, grammar, and writing, then describes the college experience that deepened her love of literature, stories, and critical thinking. A full scholarship close to home shaped her university decision, even as she sometimes wondered what it might have been like to leave Indiana. Leslie also takes us inside her years teaching ninth, tenth, and eleventh graders while earning a master's degree at Butler University. Managing crowded classrooms, mixing current events with drier material, and keeping students engaged taught her a leadership skill she still relies on: read the room, then adapt. Key Topics Covered: - Leslie Loveless's Indiana upbringing and close-knit family - The influence of her father's career as a pharmacist - Why Leslie shifted from mathematics to English in high school - Grammar, writing, and sentence structure as a bridge between analytical and humanistic thinking - Choosing a nearby university with a full scholarship - Studying literature, interpretation, and critical thinking - Earning a master's degree in English at Butler University - Teaching ninth, tenth, and eleventh grade English - Balancing classroom teaching, graduate school, grading, and coaching - Keeping teenagers engaged through varied lesson formats and current events - Reading the room as a transferable leadership skill - Why teaching began to feel too structured and all-consuming - The freedom and financial considerations behind a possible career change If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep280 Find our guest, Leslie Loveless, at these links: LinkedIn: https://www.linkedin.com/in/leslieloveless1 Slone Partners: https://slonepartners.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin OkKyojin: https://flow.page/kyojin Resources & Articles: Butler University English: https://www.butler.edu/academics/college-of-liberal-arts-sciences/english/ Purdue University College of Pharmacy: https://pharmacy.purdue.edu/ Companies, Universities, & People Mentioned: Purdue University: https://www.purdue.edu/ Butler University: https://www.butler.edu/ Timestamps: 00:00 Intro 02:59 Growing Up in Indiana 03:27 A Close-Knit Family 05:02 The Pharmacist Influence 05:46 Lessons From Her Parents 07:10 When Math Stopped Clicking 07:41 Falling for Grammar and Writing 11:42 Choosing a University Close to Home 15:26 Discovering Literature 16:02 A Future in Education 16:18 Teaching While Earning a Master's 19:18 Inside the High School Classroom 20:32 The Reality of Teaching 20:52 Keeping Teenagers Engaged…
Not rated yetThe Catalyst Mindset Behind a Lean Biotech | Örn Almarsson (4/4)
· 25 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “If I can sum up my reason to be on this Earth, it's to be a catalyst.” Moderna's rapid COVID-19 response was years in the making. Örn Almarsson explains how quiet work in mRNA manufacturing, lipid nanoparticles, bioinformatics, and vaccine development created the capabilities needed when the moment arrived. He then turns to company building at Axelyf: in vivo cell reprogramming for solid tumors, modular lipid nanoparticles, AI-informed discovery, external partners, and a deliberately lean operating model. The conversation closes with the mentors, expectations, and leadership philosophy shaping his next chapter. Key Topics Covered: - Moderna's preparation for COVID-19 - Personalized cancer vaccines - In vivo cell reprogramming - CAR T for solid tumors - Lipid nanoparticle delivery - AI-informed drug development - Capital-efficient company building - Virtual biotech operations - CDMO and CRO partnerships - Hepatocellular cancer - Mentorship and leadership - Catalyst mindset If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep279 Find our guest, Örn Almarsson, at these links: Website: https://www.axelyf.com/ LinkedIn: https://www.linkedin.com/in/orn-almarsson Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, OkKyojin: https://flow.page/kyojin Resources & Articles: National Cancer Institute: CAR T-cell therapy: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells BioNTech: https://www.biontech.com/ Pfizer: https://www.pfizer.com/ NCBI Molecular Biology reference: https://www.ncbi.nlm.nih.gov/books/NBK21054/ Companies, Universities, & People Mentioned: Moderna: https://www.modernatx.com/ BioNTech: https://www.biontech.com/ Pfizer: https://www.pfizer.com/ Merck: https://www.merck.com/ Transform Pharmaceuticals: https://www.transformpharma.com/ Alkermes: https://www.alkermes.com/ Lyndra Therapeutics: https://www.lyndra.com/ Johnson & Johnson: https://www.jnj.com/ Copel Farm and Biotech: https://www.copel.co/ University of Iceland: https://english.hi.is/ UC Santa Barbara: https://www.chem.ucsb.edu/ MIT: https://www.mit.edu/ Slone Partners: https://www.slonepartners.com/ Quest Diagnostics: https://www.questdiagnostics.com/ AmeriPath: https://www.ameripath.com/ Timestamps: 00:06 Intro 01:17 Moderna's Overnight Success Was Years in the Making 01:28 The Capabilities Behind Moderna's Rapid Response 01:52 From Prototype Vaccines to Personalized Cancer Vaccines 02:45 Why Moderna and BioNTech Were Ready 04:46 Leaving Moderna for the Next Challenge 06:16 Axelyf's In Vivo Cell Reprogramming Strategy 07:49 Building a Modular Lipid and Cargo Toolkit 08:09 Targeting Difficult Cancers and Faster Development 10:06 Staying Small, Virtual, and Capital Efficient 10:26 Using AI to Improve Lipid Nanoparticle Models 12:22 Choosing Specialized Partners Over One-Stop Shops 13:05 External…
Not rated yetThe Delivery Problem Behind Moderna's Breakthrough | Örn Almarsson (3/4)
· 29 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “You've gotta get in the house without the alarms going off.” Örn Almarsson compares therapeutic mRNA delivery to a covert package drop: the payload has to reach the right room, release its contents, and leave without triggering the immune system. He looks back at Johnson & Johnson, Alkermes, and the relationships that shaped his next move. A referral from Bob Langer led him to Moderna, where he joined a small team working through one of biotech's hardest engineering problems. The conversation covers layoffs, company transformation, patent cliffs, biotech's feast-and-famine cycles, modified mRNA, and the effort required to scale production from tiny academic batches to grams and kilograms. Key Topics Covered: - Johnson & Johnson's acquisition-driven model - Organic and inorganic growth - Alkermes company transformation - Leadership through layoffs and change - ARISTADA and long-acting injectables - Biotech volatility and patent cliffs - Regulatory exclusivity and biosimilars - Asset-focused biotech investing - Moderna's early delivery team - Therapeutic mRNA delivery - mRNA manufacturing scale-up - Modified mRNA and immune response If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep278 Find our guest, Örn Almarsson, at these links: Website: https://www.axelyf.com/ LinkedIn: https://www.linkedin.com/in/orn-almarsson Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, OkKyojin: https://flow.page/kyojin Resources & Articles: Nobel Prize: discoveries concerning mRNA vaccines: https://www.nobelprize.org/prizes/medicine/2023/press-release/ Alkermes: https://www.alkermes.com/ Johnson & Johnson: https://www.jnj.com/ NCBI Molecular Biology reference: https://www.ncbi.nlm.nih.gov/books/NBK21054/ Companies, Universities, & People Mentioned: Johnson & Johnson: https://www.jnj.com/ Merck: https://www.merck.com/ MIT: https://www.mit.edu/ Eli Lilly: https://www.lilly.com Alkermes: https://www.alkermes.com/ Harvard Business School: https://www.hbs.edu/ Moderna: https://www.modernatx.com/ Flagship Pioneering: https://www.flagshippioneering.com/ Amazon: https://www.amazon.com/ UPS: https://www.ups.com/ Timestamps: 00:06 Intro 01:28 Johnson & Johnson's Acquisition-Driven Model 02:25 Organic Growth, Acquisitions, and Commercialization 04:20 Why Pharma's Growth Strategy Keeps Changing 05:05 Leaving Johnson & Johnson for Alkermes 07:45 Transforming Alkermes Through a Hard Reset 10:03 ARISTADA and the Case for Embracing Change 10:38 Biotech's Volatility and Patent Cliffs 14:26 Regulatory Exclusivity and Biosimilars 16:00 The Shift Toward Asset-Focused Biotech 17:16 The Call That Led to Moderna 20:35 The Delivery Challenge for Therapeutic mRNA 22:48 Scaling mRNA From Micrograms to Kilograms 25:29 Modified mRNA and the Future of RNA Medicine 27:47 Outro The Biotech Startups Podcast gives you a front-row…
Not rated yetLeaving Merck to Build a Biotech From Scratch | Örn Almarsson (2/4)
· 30 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “You gotta build that over time thoughtfully.” Örn Almarsson explains why thoughtful networking matters, especially when you don't need anything right away. He also reflects on evolving professional networks, learning from failure, and the entrepreneurial culture that drew him to the United States. At Merck, a three-month visa detour exposed Örn to another laboratory and reinforced the value of adaptability. He then describes leaving a secure role for Transform Pharmaceuticals, building a small team and collaborative culture, developing new formulation technologies, and helping create the patents and assets that led to a Johnson & Johnson acquisition. Key Topics Covered: - Thoughtful networking - Professional relationships - Learning from failure - Entrepreneurial culture - Merck R&D - Visa challenges - Interdisciplinary collaboration - Startup formation - Hiring and company culture - Pharmaceutical materials discovery - Patents and licensing - Johnson & Johnson acquisition If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep277 Find our guest, Örn Almarsson, at these links: Website: https://www.axelyf.com/ LinkedIn: https://www.linkedin.com/in/orn-almarsson Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, OkKyojin: https://flow.page/kyojin Resources & Articles: Merck: https://www.merck.com/ Johnson & Johnson: https://www.jnj.com/ MIT: https://www.mit.edu/ Excedr partner network: https://www.excedr.com/partners Companies, Universities, & People Mentioned: Merck: https://www.merck.com/ Transform Pharmaceuticals: https://www.transformpharma.com/ Johnson & Johnson: https://www.jnj.com/ Massachusetts Institute of Technology: https://www.mit.edu/ Timestamps: 00:06 Intro 02:10 Networking Through Curiosity 03:46 Growing A Living Network 04:54 Learning From Failure 06:05 Entrepreneurial Risk And Meritocracy 07:01 The Merck Visa Detour 09:21 Merck's Fast R&D Culture 12:08 Working Across Disciplines 13:48 The University Of Merck 15:20 Leaving A Secure Role 19:42 Building Transform 21:53 Experience Before Startup Leadership 23:40 Transform's Mission And Culture 26:42 Patents, Licensing, And Exit 29:49 Outro The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup lessons, each episode explores what it really takes to grow a life science company—from pre-seed to IPO.
Not rated yetHow a Guitarist Became a Drug Delivery Pioneer | Örn Almarsson (1/4)
· 25 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “Perfect is the enemy of good. How do we get there?” Örn Almarsson traces the early experiences that shaped his approach to science, from growing up in Iceland and Denmark to playing electric guitar and discovering a deeper curiosity about chemistry. He describes his first research opportunity at the University of Iceland, an early industry project in Copenhagen, and the mentors who pushed him toward bioorganic chemistry. The conversation follows his move to UC Santa Barbara, his work with Tom Bruice and Alex Klibanov, and the networking connection that led to Merck. Key Topics Covered: - Growing up in Iceland and Denmark - Electric guitar and playing in bands - The influence of family in pharmaceuticals - Studying chemistry at the University of Iceland - First research experience with lipids - Haraldsson as an early mentor - Early exposure to industry - Practical and applied science - Choosing graduate school in the United States - Bioorganic chemistry at UC Santa Barbara - Mentorship and solving overlooked problems - Networking and finding a role at Merck If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep276 Find our guest, Örn Almarsson, at these links: Website: https://www.axelyf.com/ LinkedIn: https://www.linkedin.com/in/orn-almarsson Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, OkKyojin: https://flow.page/kyojin Resources & Articles: NCBI Molecular Biology reference: https://www.ncbi.nlm.nih.gov/books/NBK21054/ UC Santa Barbara Department of Chemistry: https://www.chem.ucsb.edu/ MIT Department of Chemistry: https://chemistry.mit.edu/ University of Iceland: https://english.hi.is/ Merck: https://www.merck.com/ Companies, Universities, & People Mentioned: University of Iceland: https://english.hi.is/ Novo: https://www.novonordisk.com/ Novozymes: https://www.novonesis.com/ UC Santa Barbara: https://www.chem.ucsb.edu/ MIT: https://www.mit.edu/ Merck: https://www.merck.com/ Transform Pharmaceuticals: https://www.transformpharma.com/ Alkermes: https://www.alkermes.com/ Lyndra Therapeutics: https://www.lyndra.com/ Moderna: https://www.modernatx.com/ Johnson & Johnson: https://www.jnj.com/ Berklee School of Music: https://www.berklee.edu/ UChicago: https://www.uchicago.edu/ Timestamps: 00:06 Intro 03:06 Growing Up in Iceland and Denmark 05:05 Electric Guitar, Bands, and the Pull of Science 08:40 A Family Connection to Pharmaceuticals 09:33 Choosing Chemistry at the University of Iceland 11:06 Haraldsson and the First Lipid Research Experience 12:40 An Early Introduction to Industry 14:03 Why Practical Science Mattered 14:46 Finding a Graduate Program in the United States 16:11 Tom Bruice and the Foundations of Bioorganic Chemistry 18:13 Inside a Demanding Chemistry Lab 19:38 Music, Visibility, and Academic Witness Protection 21:12 From Santa Barbara to an MIT Postdoc 22:53…
Not rated yetDon't Build Your Own Cathedral: The Hidden Cost of Lab Space | Philip Borden (4/4)
· 43 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. “Don't build your own cathedral.” After more than two decades in healthcare investing, Philip Borden decided to become an operator. He explains how a conversation with longtime friend Jeff Behrens led him to Labshares and why the shared lab model immediately resonated with his experience watching biotech companies struggle with infrastructure. Philip breaks down the hidden costs of traditional lab leases, from equipment maintenance and utilities to medical waste, freezer alarms, and unused square footage. He explains how flexible space can help emerging companies stay focused on milestones while preserving critical capital. The conversation closes with lessons from Labshares' first day under new ownership, including the loss of a major customer, the evolution of the company's value proposition, and the importance of transparent relationships with vendors. Philip also reflects on resilience, family, and the advice from his father to dream big. Key Topics Covered: - Becoming a Biotech Operator - The Acquisition of Labshares - Shared Lab Space - Capital Efficiency - Total Cost of Lab Ownership - The Cathedral Problem - Flexible Contracts - Founder and Vendor Relationships - Search Funds and Private Equity - Resilience Through Biotech Cycles If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep275 Find our guest, Philip Borden, at these links: LinkedIn: https://www.linkedin.com/in/philipborden Website: https://www.labshares.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Labshares: https://www.labshares.com/ LabCentral: https://labcentral.org/ UW CoMotion: https://comotion.uw.edu/ Pacific Lake Partners: https://www.pacificlake.com/ Harvard Business School: https://www.hbs.edu/ Duke University: https://www.duke.edu/ Excedr Partner Network: https://www.excedr.com/partners Companies, Universities, & People Mentioned: Riverside Partners: https://www.riversidepartners.com Galen Partners: https://www.galen-partners.com Frazier Healthcare Partners: https://www.frazierhealthcare.com LabCentral: https://labcentral.org UW CoMotion: https://comotion.uw.edu Pacific Lake Partners: https://www.pacificlake.com Harvard Business School: https://www.hbs.edu Duke University: https://www.duke.edu Wells Fargo: https://www.wellsfargo.com JPMorgan: https://www.jpmorgan.com Moderna: https://www.modernatx.com Lyndra Therapeutics: https://www.lyndra.com Jeff Behrens: https://www.linkedin.com/in/jeffbehrens Paul Graham: https://www.paulgraham.com Timestamps: 00:00 Intro 01:43 The Post-2008 Crash and Changing LP Base 03:16 Riverside, Galen, and the Impact of COVID 04:25 How Jeff Behrens Started Labshares 05:19 Why Labshares Resonated with Philip 07:55 Let Scientists Focus on Science 10:01 The Total Cost of Owning Lab Space 11:54 From…
Not rated yet